| GEN |
Genmab, de Deense parel
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?Wed, April 2, 2025 at 3:47 PM GMT+2 6 min We recently published a list of 7 Most Profitable Biotech Stocks To Buy Righ...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Genmabs recommendation is downgraded to underperform by Bernstein - price target lowered to DKK 580.1/4 11:16Genmabs recommendation and price target are being shaved off by B...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after ChemotherapyMedia Rele...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
GENMAB/NYKREDIT MARKETS: PRICE TARGET REDUCED TO 2000 DKK FROM 2300 DKK....
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Genmab has had its price target lowered to DKK 2,000 from DKK 2,400 by Jyske Bank, which is maintaining its buy recommendation for the stock, according to Bloomberg News....
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Genmab has had its price target for its US listing lowered to $25 from $31 by Morgan Stanley.This is reported by Bloomberg News.The recommendation remains balanced.The lowered price ...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Fyi …. JPMorgan keeps a Neutral rating on Genmab (GMAB) with a DKK 1700 price target after the company announced that Johnson Johnson (JNJ) has decided not to opt-in...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Kan iemand de link toesturen van de in het engels vertaalde Pro Investor Genmab Forum …...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Kan iemand de link naar de engelse variant van de Pro Investor Genmab Forum met mij delen …...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Company Announcement Net sales of DARZALEX ® in the third quarter of 2024 totaled USD 3.016 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, De...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Genmab has its stock recommendation lowered to neutral by JPMorgan20/8 06:54Genmab has had its share recommendation lowered by financial house JPMorgan to neutral from &quo...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
JPMs 10% downgrade may be a result of the gradual weakening of the USD, which most expect to continue in line with the interest rate cuts. This will affect Genmabs share price negatively in ...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Another one … BTIG analyst Kaveri Pohlman raised the price target on Genmab A/S (NASDAQ: GMAB) to $47.00 (from $46.00) while maintaining a Buy rating...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Fyi … UBS Remains a Buy on Genmab A/S Jun. 26, 2024, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S today and set a price target of DKK2,750.00....
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Hai Irene, weet je ook in welke size Genmab Board Member Anders Peters zijn holding heeft teruggebracht … uit persbericht van 11 juni blijkt dat hij maar slechts 2.000 aandelen heeft verkocht op gem....
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Xian Deng from UBS: Genmab Buy DKK 2,750.00 Maintained Today...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
From Nordeas morning commentary: Genmab (team) - Over the weekend, at the ASCO24 conference in Chicago, Genmab and BioNTech presented updated phase II data for acasunlimab (GEN1046), a PD-L1x4-1B...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
DNB lowers PT Genmab from DKK 2,630 to DKK 2,600 Buy...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-smal...
|
Sleutel1 |
| GEN |
Genmab, de Deense parel
Beste Highlands, zou je deze ook met ons kunnen delen. Alvast bedankt!...
|
Sleutel1 |